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In September 2015, 4CMenB meningococcal vaccine was 
introduced into the United Kingdom infant immunization 
program without phase 3 trial information. Understand-
ing the effect of this program requires enhanced surveil-
lance of invasive meningococcal disease (IMD) Neisseria 
meningitidis isolates and comparison with prevaccina-
tion isolates. Bexsero Antigen Sequence Types (BASTs) 
were used to analyze whole-genome sequences of 3,073 
prevaccine IMD N. meningitidis isolates obtained dur-
ing 2010−2016. Isolates exhibited 803 BASTs among 31 
clonal complexes. Frequencies of antigen peptide variants 
were factor H binding protein 1, 13.4%; Neisserial heparin-
binding antigen 2, 13.8%; Neisseria adhesin A 8, 0.8%; 
and Porin A-VR2:P1.4,10.9%. In 2015−16, serogroup B 
isolates showed the highest proportion (35.7%) of exact 
matches to >1 Bexsero components. Serogroup W iso-
lates showed the highest proportion (93.9%) of putatively 
cross-reactive variants of Bexsero antigens. Results high-
lighted the likely role of cross-reactive antigens. BAST sur-
veillance of meningococcal whole-genome sequence data 
is rapid, scalable, and portable and enables international 
comparisons of isolates.
Neisseria meningitidis is an accidental human pathogen that is carried asymptomatically in the nasopharynx of 
1%–40% of the population, depending on age and social 
behavior (1,2). In England and Wales, invasive meningo-
coccal disease (IMD), comprising septicemia, meningitis, 
or both, develops in ≈2 persons/100,000 population/year 
(3). Patients might have nonspecific symptoms early in 
their illnesses, but their clinical conditions can deteriorate 
rapidly, with case-fatality rates of 5%–17% and physical 
and psychological sequelae in one third of surviviors (3–5). 
Consequently, vaccination represents the optimal strategy 
for IMD prevention.
Meningococci are commonly characterized according 
to their expressed capsular polysaccharides, which define 
serogroups; 6 serogroups (A, B, C, W, X, and Y) cause most 
cases of IMD. The capsular antigens are major virulence fac-
tors, and efficacious A, C, W, and Y polysaccharide−based 
vaccines are used worldwide. However, serogroup B cap-
sular polysaccharides are poorly immunogenic and share 
structural similarity to carbohydrates found in human tissues 
(6). The first serogroup B vaccines were derived from outer 
membrane vesicles (OMVs) for use in epidemics caused by 
single strains defined by genotype and Porin A (PorA) type 
(7). Genotype or clonal complex (CC), identified by mul-
tilocus sequence typing (MLST), groups related organisms 
and is useful for categorizing IMD phenotype, antimicrobial 
drug resistance, and vaccine antigens (8,9).
The United Kingdom and Ireland are among high-in-
come countries with the highest incidence of IMD (10). The 
United Kingdom has low-incidence endemic disease and 
periods of hyperendemicity, which changes with frequency 
of hyperinvasive bacterial genotypes (10). Historically, en-
demic serogroup B IMD predominated and was caused by 
multiple CCs, especially hyperinvasive lineages CC41/44, 
CC269, CC213, and CC32 (10). In the 1990s, hyperendemic 
serogroup C IMD caused by CC11 (C:CC11) prompted intro-
duction of infant meningococcal C conjugate vaccination and 
a catch-up campaign, which reduced disease incidence and 
carriage of C:CC11 (11). The United Kingdom experienced 
another period of hyperendemicity starting in 2012 with in-
creasing incidence of W:CC11, lineage 11.1 meningococci, 
first identified in South America (12).
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The diversity of CCs responsible for IMD renders 
OMVs derived from a single CC insufficient to provide 
broad protection. Alternative vaccine candidates have 
been developed. These candidates are composed of sub-
capsular proteins prevalent among many N. meningitidis 
strains. However, their protective potential has been com-
plicated by meningococcal diversity (13–15). Two vac-
cines were licensed in 2013: 4CMenB (Bexsero; Glaxo-
SmithKline, Brentford, UK) for infants in Europe and 
bivalent recombinant lipoprotein rLP2086 (Trumenba; 
Pfizer, New York, NY, USA) for persons 10–25 years 
of age in the United States (16–18). The 4CMenB vac-
cine contains multiple proteins: factor H binding protein 
(fHbp); Neisserial heparin-binding antigen (NHBA); 
Neisseria adhesin A (NadA); and PorA P1.7–2,4 from the 
New Zealand OMV vaccine (MeNZB) (16). The rLP2086 
vaccine contains 2 fHbp variants, 1 each from subfamily 
A (A05) and subfamily B (B01) (17).
Bexsero was implemented into the United Kingdom 
immunization schedule on September 1, 2015, as a 2-dose 
priming course for infants at 2 and 4 months of age and a 
booster at 12 months of age, intended as an efficacious strat-
egy for those at highest risk within the constraints of cost-
effectiveness (18). As with previously licensed meningococ-
cal vaccines, efficacy studies were precluded because of the 
rarity of IMD, and the Meningococcal Antigen Typing Sys-
tem (MATS) was developed, which estimated 73% (95% CI 
57%–87%) vaccine coverage for UK isolates (19,20).
An appreciation of meningococcal antigenic diver-
sity and persistence over time is required to determine 
the degree and longevity of coverage provided by protein 
vaccines. Real-time, continuous, and high-throughput 
methods are needed to identify characteristics of circulat-
ing meningococci on a national scale, especially the fre-
quency distribution of vaccine antigens. This characteriza-
tion can be performed rapidly and reproducibly by using 
whole-genome sequencing (WGS) of IMD N. meningitidis 
isolates, for which data are publicly available online in the 
PubMLST database (https://pubmlst.org/neisseria) (21).
A novel nomenclature, Bexsero Antigen Sequence 
Types (BASTs), was devised to describe Bexsero antigenic 
variants (22). There were strong, nonoverlapping associa-
tions between BAST and CC, with an estimated 58.3%–
60.3% Bexsero coverage including the antigenic variants 
in Bexsero or cross-reactive variants (22). We cataloged 
genomic diversity of Bexsero vaccine antigens by using 
web-accessible platforms incorporating BAST. This study 
provides a reference point for changes in population struc-
ture of IMD-causing meningococci in the United Kingdom 
before introduction of Bexsero.
Materials and Methods
A total of 3,073 meningococci were isolated from cul-
ture-confirmed IMD cases in the United Kingdom dur-
ing epidemiologic years (July 1−June 30) 2010–2016. 
For the purposes of this study, the prevaccine period 
includes 2015−16 because implementation of Bexsero 
started on September 1, 2015, and many infants were not 
fully vaccinated during the peak IMD season (December 
2015−February 2016). The 3,073 isolates represented 
≈55% of laboratory-confirmed cases of IMD (Table 1) 
because recovery of isolates reflects differential survival 
in artificial media, susceptibility to antimicrobial drugs 
given before venipuncture, or small-volume pediatric 
blood cultures.
Genomic Analysis
WGS was part of the Meningitis Research Foundation 
Meningococcus Genome Library initiative (10). Ge-
nomes were assembled by using Velvet and VelvetOpti-
miser, uploaded to the PubMLST database, and annotated 
by using Neisseria Sequence Typing Database numbers 
(NEIS) for all loci. Analysis was undertaken by using the 
gene-by-gene approach with the Bacterial Isolate Genome 
Sequence Database to determine sequence type (ST), CC, 
and strain designation (21,23). Each isolate had associ-
ated provenance and phenotype data, including year, se-
rogroup, and region.
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Table 1. Geographic distribution of culture-confirmed invasive meningococcal disease isolates that have undergone whole-genome 
sequencing, United Kingdom, 2010–2016* 
Year 
No. isolates by region† 
 
No. laboratory-confirmed 
cases (% isolates) 
 
Serogroup, no. isolates‡ 
1 2 3 4 Total PHE PHS A B C E NG W W/Y X Y Z 
201011 464 37 36 13 550  1,009 (46.0) 76 (47.4)  1 423 13 1 5 27 2 1 76 1 
201112 370 28 30 11 439  730 (50.7) 56 (53.6)  0 311 18 1 4 32 1 0 72 0 
201213 415 29 34 13 491  769 (54.0) 66 (51.5)  0 325 29 0 7 51 1 0 78 0 
201314 367 27 30 12 436  636 (57.7) 60 (50.0)  0 240 24 0 1 92 2 0 77 0 
201415 483 19 55 15 572  724 (66.7) 65 (84.6)  0 283 23 0 5 172 2 0 87 0 
201516 488 23 62 12 585  805 (60.6) 99 (62.6)  0 238 34 2 8 197 2 0 104 0 
Total 2,587 163 247 76 3,073  4,673 (55.4) 442 (55.9)  1 1,820 141 4 30 571 10 1 494 1 
*Laboratory-confirmed cases included culture-confirmed and PCR-confirmed cases. Data included in this study represented 55.4% of all laboratory-
confirmed cases in England and 55.9% of those in Scotland. NG, nongroupable; PHE, Public Health England; PHS, Public Health Scotland. 
†1, England; 2, Wales; 3, Scotland; 4, Northern Ireland. 
‡W/Y serogroups were combined because of inconclusive serogrouping results. 
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We assigned BASTs as described (22). Nucleotide se-
quences of fhbp, nhba, nadA, and porA variable regions 1 
and 2 (VR1 and VR2) were translated to deduce peptide 
sequences, and variant numbers were assigned by using 
established nomenclatures (24–26). Unique combinations 
of the 5 components were assigned a BAST number in or-
der of discovery; BAST-1 corresponds to the vaccine con-
stituents: fHbp 1, NHBA 2, NadA 8, and PorA 7–2,4 (22). 
Data were manually curated to confirm the absence of fhbp, 
nhba, nadA, and porA, and isolates were assigned peptide 
designation 0 (null). If nucleotide sequences contained a 
frameshift mutation, peptide designation 0 (null) was as-
signed. Peptide variants were not assigned if the complete 
gene was not available because of sequencing or assembly 
issues (22,27).
For assessment of Bexsero antigenic variants expected 
to be prevented by vaccination (coverage), we compared 
the genotypic profile (BAST) of isolates with those of vac-
cine antigenic variants. The term exact match indicates 
isolates having >1 of 4 Bexsero antigenic variants (fHbp 
1, NHBA 2, NadA 8, and PorA-VR2:4). The term cross-
reactive match indicates isolates having >1 variant that 
can potentially be recognized by Bexsero-induced antibod-
ies, demonstrating a possible cross-protective immune re-
sponse in humans. 
These variants were previously identified by using 
MATS analysis, which at the time of writing, was the 
most extensively used method for assessing qualitative 
and quantitive differences in antigens (20,28,29). Vari-
ants were considered putatively cross-reactive; fHbp 
peptides 4, 13, 14, 15, 37, 232 and NadA variants 1 or 
2/3. NadA peptides were included because of potential 
discrepancies between in vitro and in vivo NadA ex-
pression (20,30). Cross-reactive NHBA peptides were 
not included because of lack of data on the breadth of 
peptides covered by Bexsero. Genomic analysis has not 
been used to infer protein expression or immunologic 
cross-reactivity per se.
We performed all statistical analyses by using R soft-
ware version 3.2.4 (https://www.r-project.org/). We calcu-
lated the Simpson index of diversity by using the Vegan 
package in R software to assess diversity of BAST; values 
closer to 1 indicated greater diversity.
Nomenclature of Antigenic Variants
There are 3 systems for classifying fHbp variants. The 
first system described 3 variants (1–3) on the basis of 
sequence similarity and cross-reactivity in serum bacte-
ricidal antibody (SBA) assays (31). The second system 
described 2 subfamilies, A and B (32). The third system, 
used in our study as part of the BAST scheme, assigned 
arbitrary numerical integers to unique deduced peptide 
sequences independent of variant/subfamily (24). NHBA 
peptide variants were assigned arbitrarily to unique pep-
tide sequences. Updated nomenclature for NadA de-
scribed 4 variants on the basis of peptide sequence homol-
ogy: NadA-1, NadA-2/3, NadA-4/5, and NadA-6 (26). 
PorA nomenclature was based on nucleotide and peptide 
sequence homology and recognized the previous serolog-
ic classification: P1, followed by VR1 family-variant, and 
VR2 family-variant (e.g., P1.7–2,4) (25). All nomencla-
ture is available in the PubMLST database.
Results
Distribution of Bexsero Vaccine Antigens
For 2,922 isolates (95.1%), MLST, which was deduced 
from WGS data, identifed 645 STs with 2,866 (93.3%) iso-
lates assigned to 1 of 31 CCs. We found variation in CC 
distribution over the 6-year period, with a 10-fold increase 
in CC11 and decreases in CC41/44 (172 to 56, 50.0%) and 
CC269 (108 to 52, 51.8%), which accounted for most sero-
group B isolates (Figure 1).
fHbp Peptide
An fhbp gene was present in 3,065 (99.7%) isolates, absent 
in 5 (1.6%), and not assigned in 3 (0.1%) because of in-
complete sequence assembly. Across all serogroups, vari-
ant 2 fHbp peptides increased over the 6-year period, but 
most markedly in 2014−15 (313/572, 54.7%) and 2015−16 
(347/585, 59.3%). From 2010−11 through 2012−13, vari-
ant 1 peptides predominated; from 2013−14 onwards, vari-
ant 2 peptides were more frequent than variant 1 peptides 
(Figure 2, panel A). Overall, there were 207 unique fHbp 
peptides in the collection: 109 variant 1, 43 variant 2, 54 
variant 3, and 1 between variants 2 and 3.
Variant 1 peptides were present in 1,389 (45.3%) of 
3,065 isolates, and 5 peptides accounted for 1,144 (82.4%) 
of 1,389 isolates: 4 (399, 28.7%), 13 (329, 23.7%), 15 (184, 
13.2%), 14 (127, 9.1%), and 1 (105, 7.6%). The contribu-
tion of these 5 peptide variants among IMD N. meningiti-
dis isolates decreased from 278 (50.5%) of 550 isolates 
in 2010−11 to 154 (26.3%) of 585 isolates in 2015−16. 
Peptide 4 was predominantly associated with B:CC41/44, 
whereas peptides 13 and 15 were mainly associated with 
B:CC269. Peptide 1, the variant in Bexsero, was present 
in 105 isolates, predominantly B:CC32, and decreased in 
incidence from 25 (4.5%) of 550 isolates in 2010−11 to 13 
(2.2%) of 585 isolates in 2015−16.
Variant 2 peptides were present in 1,404 (45.8%) of 
3,065 isolates; 6 peptides (22, 25, 19, 16, 21, and 24) ac-
counted for 1,323 (94.2%) of 1,404 isolates. Peptide 22 
(predominantly W:CC11) increased 13-fold from 15 iso-
lates in 2010−11 to 198 isolates in 2015−16. Peptide 25, 
associated with Y:CC23, was consistently present through 
the period.
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Variant 3 peptides were present in 274 (8.9%) of 3,065 
isolates. Peptides 45, 47, and 31 were the most frequently 
occurring (predominantly B:CC213 and B:CC461).
NHBA Peptide
The nhba gene was present in 2,986 (97.2%) isolates; 87 
isolates were not assigned an allelic variant because of 
incomplete sequence assembly. There were 163 unique 
NHBA peptides, and 4 isolates were assigned null (0), 
considered unlikely to express functional proteins be-
cause of frameshift mutations in the nhba coding region. 
The most frequently occurring peptide was 29 (568/2,986, 
19.0%), which increased 7-fold during the study period 
and was associated with W:CC11. The second most com-
mon was peptide 2, the variant in Bexsero, which de-
creased in incidence from 111 (20.2%) of 550 isolates in 
2010−11 to 50 (8.5%) of 585 isolates in 2015−16; most 
(411/424) isolates belonged B:CC41/44. Other prevalent 
NHBA variants were 7, 17, 21, 20, and 18, which, with 
29 and 2, accounted for 2,258 (75.6%) of 2,986 isolates 
(Figure 2, panel B).
NadA Peptide
We found 2,036 (66.3%) isolates in which nadA was ab-
sent, 34 (1.1%) with an insertion element, and 38 (1.2%) 
not assigned an allelic variant because of incomplete se-
quence assembly. A total of 2,128 (69.2%) isolates were 
assigned NadA peptide null (0) because of absence of nadA 
genes or presence of frameshift mutations or insertion el-
ements disrupting the coding sequence. Of the prevalent 
CCs, NadA peptide was absent from all isolates belonging 
to CC41/44, CC23, CC22, CC162, CC35, CC167, CC103, 
and CC282. Of the 907 (29.5%) isolates with NadA pep-
tides present, there were 135 (4.4%) NadA-1 variants, 592 
(19.3%) NadA-2/3 variants, and 180 (5.9%) NadA-4/5 
variants; there were no NadA-6 variants (Figure 2, panel 
C). The proportion of isolates with NadA peptides in-
creased from 96 (17.5%) of 550 isolates in 2010−11 to 257 
(43.9%) of 585 isolates in 2015−16. Among these isolates, 
there were 23 unique peptides. The most common, peptide 
6 (NadA-2/3), increased from 14 (2.5%) of 550 isolates 
in 2010−11 to 187 (40.0%) of 585 isolates in 2015−16. 
Peptide 79 (NadA-4/5, contained a homopolymeric tract 
resulting in phase variation) was the second most com-
mon, designated as phase variable on, and occurred in 164 
isolates, predominantly B:CC213. Peptide 8 (NadA-2/3), 
found in Bexsero, was present in 0.8% (26/3,073) of iso-
lates (Y:CC174, B:CC269, B:CC60, B:CC18, A:CC5).
PorA Peptide
The porA gene was present in 3,011 (98.0%) of 3,073 iso-
lates. For 54 isolates, no nucleotide sequence allele was 
assigned because of incomplete sequence assembly. For 
3,064 (99.7%) isolates, predicted VR1 and VR2 peptides 
were obtained. PorA-VR2 variant 4 was found in 336 
(10.9%) isolates, and showed decreasing incidence from 90 
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Figure 1. Clonal complex and serogroup distribution of invasive meningococcal disease isolates, United Kingdom, 2010–2016.  
A) Proportional contribution of each CC of disease-causing culture-confirmed meningococcal isolates by epidemiologic year.  
Other CC indicates CCs that were found in <20 isolates during the 6-year study period. B) Distribution of isolate serogroups by 
epidemiologic year. Serogroups shown had >10 isolates during the 6-year study period. Serogroups with <10 isolates (A, E, X,  
and Z) are shown in Table 1. CC, clonal complex; NG, nongroupable, W/Y, serogroups combined because of inconclusive 
serogrouping results.
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(16.5%) of 547 isolates in 2010−11 to 38 (6.5%) of 585 iso-
lates in 2015−16. PorA-VR2 variant 4 containing isolates 
were predominantly B:CC41/44 (302/336, 89.9%) but also 
B:CC162, B:CC269, B:CC213, B:CC32, and B:CC60 and 
were associated with PorA-VR1 variants 7–2 (n = 330), 17 
(n = 2), 12–3 (n = 2), 22 (n = 1), and 22–1 (n = 1) (Figure 
2, panel D).
BAST
We determined 803 unique BASTs for 2,917 (94.9%) iso-
lates. The ratio of BASTs per isolate was calculated by 
dividing the number of unique BASTs by the number of 
isolates. This ratio decreased from 0.416 in 2010−11 to 
0.265 in 2015−16. The Simpson index of diversity ranged 
from 0.976 in 2010−11 to 0.902 in 2015−16 (Table 2). We 
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Figure 2. Distribution of 4CMenB vaccine antigenic variants among invasive meningococcal disease isolates, United Kingdom, 
2010–2016. A) Proportion of isolates with fHbp variants 1, 2, and 3 by epidemiologic year. Peptide 1 is found in the Bexsero 
4CMenB vaccine (GlaxoSmithKline, Bentford, UK), and cross-reactive variants included in this analysis are all variant 1 peptides. 
B) Proportion of isolates with the 7 most prevalent NHBA peptides by epidemiologic year; all other peptide variants are in “other.” 
Peptide 2 is contained in Bexsero. C) Proportion of isolates with NadA variants 1, 2/3, and 4/5 by epidemiologic year; there were 
no isolates with NadA variant 6. Peptide 8 (variant 2/3) is contained in Bexsero. Values above columns indicate number of unique 
peptides. D) Frequency distribution of PorA-VR1 (horizontal axis) and PorA-VR2 (vertical axis) variants. Variants shown were 
those that had >20 isolates in the collection from the United Kingdom during 2010–2016. Bexsero contains the MeNZB OMV 
vaccine components, including variants PorA P1.7–2,4. Color scales show the frequency of isolates from highest (green) to lowest 
(red). fHbp, factor H binding protein; NadA, Neisseria adhesin A; NHBA, Neisserial heparin-binding antigen; OMV, outer membrane 
vesicles; PorA, porin A.
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found strong, nonoverlapping association of BAST and 
CC (Figure 3). When we compared BAST prevalence pre-
implementation (cases during July 1, 2010−September 1, 
2015) and postimplementation (cases during September 
1, 2015−June 30, 2016), we found statistically significant 
increases in BAST-2 (CC11), BAST-221 (CC23), BAST-
232 (CC41/44), and BAST-8 (CC11) and a decrease in 
BAST-220 (CC41/44) (Figure 4).
BAST Distribution by Serogroup
Although Bexsero is licensed for serogroup B IMD, its 
components might be present on the surface of menin-
gococci, independent of capsular type. Therefore, we 
analyzed distribution of Bexsero antigens by serogroup. 
Serogroup B isolates had the highest proportion of exact 
matches to >1 Bexsero antigen: 155 (36.6%) of 423 isolates 
in 2010−11 and 85 (35.7%) of 238 isolates in 2015−16, pre-
dominantly CC41/44. The proportion of isolates with exact 
or potentially cross-reactive antigens was 293 (69.3%) of 
423 isolates in 2010−11 and 149 (62.6%) of 238 isolates in 
2015−16 and represented CC269, CC41/44, CC32, CC213, 
CC60, CC1157, CC18, CC162, CC11, CC461, CC35, 
CC167, and CC254. The potentially cross-reactive variants 
included fHbp peptides 4, 13, 14, and 15 (956/1,144) and 
NadA peptide 1 (118/1,144).
For serogroup C, 8/141 isolates had >1 exact match to 
Bexsero components, but numbers varied each year depending 
on predominant CC. There were 2 (15.4%) of 13 matches to 
Bexsero components in 2010−11 and 3 (13.0%) of 23 match-
es to Bexsero components in 2014−15; isolates belonged 
to CC32. No isolates were exact matches in 2011−12 and 
2015−16 (predominantly CC11). The proportion of isolates 
also having potentially cross-reactive antigens increased from 
4 (30.8%) of 13 in 2010−11 to 25 (91.3%) of 34 in 2014−15. 
The antigenic variants were fHbp (50 isolates, predominantly 
peptide 13) and NadA (50 isolates, predominantly peptides 
121, 127, and 1), largely reflecting secular changes in CC dis-
tribution with increases in CC11, CC269, CC32, and CC174.
Of 571 serogroup W isolates, 1 (0.2%) CC11 isolate 
was an exact match to Bexsero components (fHbp 1). 
When we included matches to potentially cross-reactive 
antigens, there were 14 (51.9%) of 27 isolates in 2010−11, 
which increased to 185 (93.9%) of 197 isolates in 2015−16. 
This increase was caused by NadA 6 in 500 (87.6%) of 
571 isolates and fHbp 13 in 7 (1.2%) of 571 isolates, all of 
which belonged to lineage 11.1, W:CC11.
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Table 2. Number of unique BASTs and measures of diversity among invasive meningococcal disease isolates, United Kingdom, 
2010–2016* 
Epidemiologic year No. unique BASTs No. isolates No. BASTs/isolate Simpson index of diversity 
201011 229 550 0.416 0.976 
2011–12 187 439 0.426 0.977 
2012–13 226 491 0.460 0.976 
2013–14 181 436 0.415 0.960 
2014–15 199 572 0.348 0.924 
2015–16 155 585 0.265 0.902 
Total 803 3,073 0.261 0.963 
*BASTs, Bexsero Antigen Sequence Types. 
 
Figure 3. Nonoverlapping 
association of BAST and CC 
among invasive meningococcal 
disease isolates, United 
Kingdom, 2010–2016. Frequency 
distribution of BAST by CC for the 
7 most frequently found CCs that 
represent 82.4% (2,533/3,073) 
of culture-confirmed invasive 
meningococcal disease isolates. 
BAST-220, -223, -4, and -19 
contain an exact match with BAST-
1. BAST-2, -8, -219, -222, -232, 
-226, -231, -229, and -236 contain 
a potentially cross-reactive match 
with BAST-1. BAST, Bexsero 
Antigen Sequence Type; CC, 
clonal complex.
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Serogroup Y disease isolates showed exact matches to 
Bexsero components in 7 (9.2%) of 76 isolates in 2010−11, 
which decreased to 3 (2.9%) of 104 isolates in 2015−16. 
When potential cross-reactive antigens were included, 
matches ranged from 9 (11.8%) of 76 isolates in 2010−11 
to 3 (2.9%) of 104 isolates in 2015−16 and represented 
CC174, CC23, CC22, and CC11.
Discussion
The requirement for vaccines to protect against serogroup 
B meningococci from multiple CCs led to development 
of multipeptide vaccines, such as 4CMenB (Bexsero) and 
bivalent rLP2086 (Trumenba) (16,17). Bexsero was intro-
duced into the UK infant immunization schedule in Sep-
tember 2015, supported by data from the MATS assay that 
estimated 73% IMD N. meningitidis isolate coverage in 
England and Wales in 2007–08 (20).
We report a comprehensive evaluation of the frequen-
cy distribution of Bexsero antigen peptide variants in IMD 
N. meningitidis isolates, which used a national collection 
of WGS of culture-confirmed cases from 2010–2016. The 
frequency distribution of individual vaccine antigens was 
correlated with the distribution of meningococcal CCs in 
the United Kingdom over time. During 2010–2016, high 
diversity of 803 BASTs and 31 CCs emphasized the broad 
coverage required of peptide-based vaccines if they are to 
protect against endemic disease caused by multiple CCs. 
The most frequently occurring BASTs (20 representing 
44.1% of serogroup B isolates) could provide useful infor-
mation for future vaccine formulations.
Bexsero components correspond to BAST-1, fHbp 
1, NHBA 2, NadA 8, PorA-VR1:7–2, and PorA-VR2:4. 
In this study, the incidence of individual BAST-1 anti-
gens in serogroup B IMD cases in the United Kingdom 
during 2010–2016 was 5.4% (99/1,820) for fHbp, 23.0% 
(419/1,820) for NHBA, 0.3% (5/1,820) for NadA, and 
18.4% (335/1,820) for PorA-VR2. Low levels of exact 
antigenic variants found in Bexsero imply that host immu-
nogenicity to cross-reactive antigens would be necessary 
to provide the level of protection required by a national 
vaccination program, although this host response is also 
dependent on adequate protein expression, which can-
not be determined solely from genomic analysis.  In vi-
tro studies comparing bactericidal killing of various fHbp 
variant 1 peptide−expressing meningococci (peptides 1, 
2, 3, 4, 5, 10, 12, 13, 14, and 15) found cross-reactivity 
in postvaccination serum samples from adults, but func-
tional activity in infants was limited to peptides 1 and 2 
after immunization at 2, 4, and 6 months of age (33). 
Surface protein expression is also a major determi-
nant of bactericidal killing. For fHbp, when heterologous 
bactericidal activity was tested, mouse antisera to peptide 
1 produced positive titers against closely related peptide 4 
regardless of expression level. For more distantly related 
peptides, such as peptide 15, higher protein expression 
was required (34).
At the time of writing, the most extensive estimation 
of cross-reactivity data for Bexsero had been collected by 
using the MATS assay. This assay quantifies expression 
and antigenic similarities of fHbp, NHBA, and NadA by 
sandwich ELISA and identifies PorA serosubtype by se-
quencing for each isolate (20,35). During development, the 
antigen measurements for fHbp, NHBA, and NadA were 
correlated to bactericidal killing with relative potency (RP) 
against 57 reference isolates tested by an SBA assay, deter-
mining likelihood of bacterial killing. Isolates with PorA-
VR P1.4 peptide were considered to be covered, without 
further serologic testing (35). Contemporaneous MATS 
estimate of coverage for IMD N. meningitidis isolates from 
the United Kingdom during 2014–15 was 66% (95% CI 
52%–80%) (28). However, the presence, cross-reactivity, 
and expression levels of antigenic variants in meningococci 
alone does not directly measure their susceptibility to bac-
tericidal killing, which is also dependent on host innate and 
adaptive immune responses, a function not measured by the 
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Figure 4. Changes in BAST prevalence before and after 
Bexsero implementation among invasive meningococcal disease 
isolates, United Kingdom, 2010–2016. Frequency of BASTs is 
shown for the period before implementation of Bexsero vaccine, 
July 2010–August 2015 (dark blue), and after implementation, 
September 2015–June 2016 (light blue). The most frequently 
occurring BASTs preimplementation were 2,¶ 221, 219,¶ 220,# 
222,¶ 267, 225, 223,# 1576, and 349. The most frequent BASTs 
postimplementation were 2,¶ 221, 219,¶ 225, 220,# 232,¶ 8,¶ 
1576, 228, and 349. *p<0.00001; †p<0.01; ‡p<0.05; §p<0001; 
¶BAST contains a potentially cross-reactive match to BAST-1; 
#BAST contains an exact match to BAST-1. BASTs with significant 
changes preimplementation and postimplementation were BAST-
2 (fHbp 22, NHBA 29, NadA 6, PorA-VR1:5, and PorA-VR2:2), 
p<0.00001; BAST-221 (25; 7; 0; 5–1; 10–1), p = 0.006; BAST-
220 (4; 2; 0; 7–2; 4), p = 0.02; BAST-232 (4; 2; 0; 12–1; 16), p = 
0.01; and BAST-8 (22; 29; 121; 5; 2), p = 0.0005. BAST, Bexsero 
Antigen Sequence Type.
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MATS assay. Therefore, this assay remains a surrogate for 
estimating functional activity against cross-reactive anti-
genic variants.
Among UK isolates we examined, the most frequent 
peptide variant 1 fHbp peptides were 4, 13, 15, 14, and 1. 
For most fHbp peptide 1 isolates tested by MATS, their 
RP lies above the positive bactericidal threshold (PBT), 
and these isolates are predicted to be killed by the pooled 
serum from Bexsero-vaccinated toddlers used in the assay 
(20). However, for other fHbp variant 1 peptides, there was 
marked variation in coverage estimates by MATS for iso-
lates with the same peptide variant. Two MATS studies in 
Europe identified the RP for peptide 4 isolates to be most 
consistently above the PBT, but RP for peptide 13, 14, and 
15 isolates spanned the PBT (20,29). The degree of pro-
tection afforded by Bexsero vaccination will be observed 
through postimplementation enhanced surveillance. With 
2-dose vaccine uptake at 88.6%, early reports of vaccine ef-
ficacy were estimated to be 82.9% (95% CI 24.1%–95.2%) 
(36). If these high efficacy estimates, albeit with wide CIs, 
continue to show protection beyond that predicted by geno-
typic, phenotypic, or functional estimates, then synergistic 
activity or minor antigens might need to be considered, nei-
ther of which are quantified by MATS or BAST.
Coverage for nonserogroup B isolates by Bexsero-in-
duced immunity was of special interest in the United King-
dom because of increasing IMD cases caused by W:CC11 
from 2012, with severe and atypical IMD and high mortal-
ity rates (37). The principal change in this analysis was the 
increase of BAST-2 (22; 29; 6; 5; 2), a direct consequence 
of W:CC11 clonal expansion. Although conjugate ACWY 
vaccine was introduced in August 2015, it was targeted to 
teenagers, the age group with increased disease and high-
est risk for carriage (38). There is a paucity of supporting 
immunologic evidence for the role of Bexsero in protec-
tion against nonserogroup B isolates, but in a small case 
series of 6 W:CC11 isolates, all BAST-2, human SBA as-
say responses of >1:32 were observed by using pooled se-
rum from infants vaccinated with 3 doses of Bexsero (39). 
Therefore, some protection might be provided to Bexsero-
vaccinated infants and toddlers.
After implementation of Bexsero into the UK immu-
nization schedule, long-term vaccine effectiveness will be 
established by enhanced IMD surveillance accompanied 
by characterization of meningococcal isolates (36). The 
methods used here are rapid, standardized, open-source, 
and readily applied to different settings (22,40). Use of 
WGS in the Meningitis Research Foundation Meningococ-
cus Genome Library initiative in the United Kingdom to 
extract vaccine antigenic variant data enables rapid isolate 
characterization, surveillance of circulating meningococci, 
and monitoring of secular changes and the impact of all 
meningococcal vaccines in use (10,22). These data serve 
as a reference point against which effects of the national 
Bexsero program can be compared, and highlight reliance 
on cross-reactive variants to maintain effective protection. 
Finally, such data will be invaluable in development of 
novel vaccine formulations that ensure continued coverage.
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